186 related articles for article (PubMed ID: 7493367)
1. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
2. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
3. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
4. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
Goldenberg DM; Horowitz JA; Sharkey RM; Hall TC; Murthy S; Goldenberg H; Lee RE; Stein R; Siegel JA; Izon DO
J Clin Oncol; 1991 Apr; 9(4):548-64. PubMed ID: 2066752
[TBL] [Abstract][Full Text] [Related]
5. 131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
Lindén O; Tennvall J; Hindorf C; Cavallin-Ståhl E; Lindner KJ; Ohlsson T; Wingårdh K; Strand SE
Acta Oncol; 2002; 41(3):297-303. PubMed ID: 12195750
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
[TBL] [Abstract][Full Text] [Related]
9. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma.
Becker WS; Behr TM; Cumme F; Rössler W; Wendler J; Kern PM; Gramatzki M; Kalden JR; Goldenberg DM; Wolf FG
Cancer Res; 1995 Dec; 55(23 Suppl):5771s-5773s. PubMed ID: 7493344
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma.
Vose JM; Colcher D; Gobar L; Bierman PJ; Augustine S; Tempero M; Leichner P; Lynch JC; Goldenberg D; Armitage JO
Leuk Lymphoma; 2000 Jun; 38(1-2):91-101. PubMed ID: 10811451
[TBL] [Abstract][Full Text] [Related]
11. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
[TBL] [Abstract][Full Text] [Related]
14. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
15. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
Kaminski MS; Zasadny KR; Francis IR; Fenner MC; Ross CW; Milik AW; Estes J; Tuck M; Regan D; Fisher S; Glenn SD; Wahl RL
J Clin Oncol; 1996 Jul; 14(7):1974-81. PubMed ID: 8683227
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
17. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
[TBL] [Abstract][Full Text] [Related]
19. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
Tsai DE; Maillard I; Schuster SJ; Nasta SD; Porter DL; Klumpp TR; Goldenberg DM; Luger SM; Alavi A; Sharkey RM; Hartzell KB; Stadtmauer EA
Clin Lymphoma; 2003 Jun; 4(1):56-9. PubMed ID: 12837157
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
Illidge T; Honeychurch J; Vandersteen A; Cragg M
Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]